Aptose Biosciences
APTO
APTO was delisted on the 1st of April, 2025.
46 hedge funds and large institutions have $13.4M invested in Aptose Biosciences in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 9 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
1.74% less ownership
Funds ownership: 26.73% → 24.99% (-1.7%)
6% less funds holding
Funds holding: 49 → 46 (-3)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
67% less capital inflows, than outflows
Capital inflows: $469K | Capital outflows: $1.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sigma Planning
Ann Arbor,
Michigan
|
+$102K |
| 2 |
TI
Telemetry Investments
New York
|
+$59.6K |
| 3 |
Millennium Management
New York
|
+$56.9K |
| 4 |
Annandale Capital
Dallas,
Texas
|
+$53.7K |
| 5 |
Formidable Asset Management
Cincinnati,
Ohio
|
+$53.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$499K |
| 2 |
Sanders Morris Harris
Houston,
Texas
|
-$377K |
| 3 |
P.A.W. Capital
Greenwich,
Connecticut
|
-$336K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$41K |
| 5 |
Carlson Capital
Dallas,
Texas
|
-$29.8K |
APTO Hedge Fund Activity: Q4 2022 in Review
46 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q4 2022, worth a combined $13.4M — down 8.9% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of APTO and 5 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was Sigma Planning, adding an estimated $102K. The largest seller was Nantahala Capital Management, cutting an estimated $499K.
- 46 institutional investors held Aptose Biosciences (APTO) as of Q4 2022, down from 49 in Q3 2022.
- Funds reported $13.4M of Aptose Biosciences stock for Q4 2022, down 8.9% quarter-over-quarter.
- 5 funds opened new Aptose Biosciences positions in Q4 2022 and 9 closed out, a net change of -4 holders.
- The largest Aptose Biosciences buyer in Q4 2022 was Sigma Planning, an estimated $102K added.
- The largest Aptose Biosciences seller in Q4 2022 was Nantahala Capital Management, an estimated $499K sold.
Based on aggregated 13F filings for Q4 2022.